Retatrutide Side Effects: What the Trials Documented

Direct answer

In Eli Lilly's registered retatrutide trials, the most frequently reported side effects were gastrointestinal — nausea, diarrhea, vomiting, and constipation — and they were clearly dose-dependent, more common at higher doses and concentrated during dose escalation, mostly mild-to-moderate (human trial data, Grade B) (NEJM Phase 2, 2023; Lilly TRIUMPH-1 Phase 3, 2026). The trials also documented a modest, dose-dependent rise in heart rate that peaked around week 24 and then declined, plus low-frequency signals worth naming (transient liver-enzyme rises in ~1%, asymptomatic amylase/lipase increases, mild skin-sensitivity reports) (NEJM Phase 2, 2023). All of this describes monitored clinical-trial use under medical supervision. Retatrutide is investigational and not FDA-approved as of June 2026; material sold online as a "research peptide" carries unknowns the trials cannot speak to.

What retatrutide is, in one paragraph

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide from Eli Lilly that activates three metabolic receptors at once — those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (Lilly). That triple mechanism matters for a side-effects page in two ways. The GLP-1 and GIP arms drive the gut effects that dominate the adverse-event tables — the same class effect seen with semaglutide and tirzepatide. The glucagon arm is what most distinguishes retatrutide's safety profile, and it is the most plausible reason the trials saw a heart-rate signal. For the full mechanism, dosing-by-trial design, and efficacy, see the retatrutide monograph. This page is narrower: it covers what the published trials actually recorded about harms, graded by evidence, and how that differs from what gray-market sellers imply.

How to read this page

We separate two things the marketing collapses:

• Trial-documented effects — recorded under medical supervision in registered, peer-reviewed or company-reported trials, with dose-response data and comparison to placebo. These earn a real human-evidence grade.
• Anecdotal / gray-market reports — self-reported experiences from people using unregulated material of unverified identity and purity. These are not a safety dataset and are graded accordingly.

For how Peptevity assigns the letter grades, see our evidence-grading methodology. One standing caveat runs underneath everything below: a side-effect profile measured in a supervised trial, with a controlled product and a slow dose-escalation schedule, does not transfer to a vial of unknown research-grade powder self-administered without that scaffolding.

The headline finding: gastrointestinal, and dose-dependent — Grade B (human trial)

Across retatrutide's obesity program, the adverse-event story is consistent and unambiguous: the most frequently reported side effects were gastrointestinal, they tracked with dose, they clustered during dose escalation, and they were predominantly mild-to-moderate.

In the 48-week Phase 2 obesity trial (NEJM, 338 adults, doses of 1, 4, 8, and 12 mg vs placebo), the investigators wrote that the most frequent adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — that they "occurred more frequently with retatrutide than with placebo," "occurred primarily during dose escalation," were "predominantly mild to moderate in severity," were "more frequent in higher-dose groups," and were "partially mitigated by the use of a lower starting dose (2 mg vs. 4 mg)" (NEJM Phase 2, 2023). Any adverse event was reported in 70% of the placebo group versus 73–94% of the retatrutide groups, with the highest incidence in the 8-mg and 12-mg arms (NEJM Phase 2, 2023).

The Phase 3 TRIUMPH-1 trial (2,339 adults, an 80-week study with topline results reported by Lilly on May 21, 2026) puts numbers on the dose-response. Comparing the 4-mg, 9-mg, and 12-mg groups against placebo, the most common adverse events were (Lilly TRIUMPH-1, 2026):

The pattern is what a GLP-1/GIP-driven mechanism predicts: nausea leads, frequency generally climbs with dose, and vomiting roughly doubles from the lowest to the highest dose. (Diarrhea is the one place the gradient is not perfectly monotonic — it peaks in the 9-mg arm rather than the 12-mg arm — but every retatrutide group runs well above placebo.) The honest framing is "common, dose-related, mostly transient and mild-to-moderate, worst during the ramp-up" — not "harmless," and not "dangerous." We grade this B (limited but direct human trial data) rather than A because the long-term, post-approval safety record that an A would require does not yet exist for a drug still in Phase 3.

Discontinuations and serious events

Side effects were tolerable for most participants but not for all. In the Phase 2 trial, discontinuation of retatrutide because of adverse events occurred in roughly 6–16% of participants (climbing with dose), versus 0% on placebo, and gastrointestinal events were the most common reason (NEJM Phase 2, 2023). Serious adverse events were uncommon and similar between groups — about 4% in both the retatrutide and placebo groups; one was a case of acute pancreatitis, and a single death (a drowning) was judged by the site investigator to be unrelated to the drug (NEJM Phase 2, 2023).

The other signal the trials reported: heart rate — Grade B (human trial)

The second consistently reported finding is cardiovascular. In the Phase 2 trial, heart rate increased in a dose-dependent manner, peaking at 24 weeks and then declining through weeks 36 and 48 (NEJM Phase 2, 2023). The trial authors noted the increases "were similar to those reported for GLP-1 receptor agonists" and attributed the effect mechanistically to glucagon and GLP-1's positive chronotropic action on the heart (NEJM Phase 2, 2023). Secondary reporting of the trial data has placed the average peak increase in the range of roughly 5–7 beats per minute at the higher doses; we flag that magnitude as a secondary-source summary of the supplementary data rather than a figure we are quoting from the main NEJM text.

What the trial did not find is also part of the honest picture. Reported cardiac arrhythmias were described as mild-to-moderate, with a single exception — one severe prolonged-QT event in a participant who was also receiving ondansetron (an anti-nausea drug with its own QT liability) (NEJM Phase 2, 2023). The heart-rate rise is a real, dose-related, drug-class-typical signal that resolved over time in the trial; it is not, on the Phase 2 evidence, a demonstrated increase in serious cardiac events. Because resting heart rate is a clinically monitored vital sign, this is precisely the kind of effect that supervised trial use catches and unsupervised gray-market use does not.

Lower-frequency findings worth naming — Grade B/C

These appeared at low rates in the trials and are worth stating plainly rather than burying:

• Liver enzymes. Transient increases in alanine aminotransferase (ALT) to more than three times the upper limit of normal occurred in about 1% of retatrutide participants, and mean ALT and AST were unchanged or had decreased by week 48 (NEJM Phase 2, 2023). The companion Phase 2a study in fatty-liver (MASLD) disease reported "no hepatotoxicity signals" through 48 weeks (Nature Medicine MASLD Phase 2a, 2024 — PMC11271400). So the liver signal is small and was not, in these trials, a pattern of injury — but it is a measured laboratory finding, not a non-event.
• Pancreatic enzymes / pancreatitis. Increases in amylase and lipase were mostly asymptomatic, with the notable exception of one serious adverse event of acute pancreatitis in the Phase 2 obesity trial (NEJM Phase 2, 2023). Pancreatitis is a recognized class consideration for incretin drugs generally; the Cleveland Clinic's overview describes its symptoms and risks (Cleveland Clinic — Pancreatitis).
• Skin sensitivity. Cutaneous hyperesthesia and skin-sensitivity adverse events were reported in 7% of retatrutide participants versus 1% on placebo; none were severe or serious, and none were associated with overt skin findings (NEJM Phase 2, 2023).
• What was not seen. In the Phase 2 trial there were no cases of clinically significant hypoglycemia, no medullary thyroid cancer, and no C-cell hyperplasia reported (NEJM Phase 2, 2023). Absence of a signal in a 48-week trial of a few hundred people is reassuring but not the same as a long-term all-clear — which is why the multi-year TRIUMPH outcome trials exist.

We grade the lab and skin findings B/C: they are direct human trial observations (B), but several rest on small numbers within a single program, which tempers how far they generalize (C).

What the trials cannot tell you: the gray-market gap — Grade E (anecdotal)

Everything above describes retatrutide as studied — a defined molecule, made to pharmaceutical standards, given on a deliberately slow escalation schedule, with vital signs and bloodwork monitored. None of that applies to material bought online and labeled "research use only."

Self-reported side effects from gray-market use circulate widely, but they earn a Grade E (anecdotal) for three reasons that stack on top of one another:

• You cannot verify what is in the vial. The FDA has documented unapproved, misbranded GLP-1-class peptide products sold online, and Lilly warns that illicit retatrutide "may contain unknown ingredients, harmful contaminants and impurities" and "may also have too much or too little active ingredient, or the wrong ingredient entirely" (Lilly; see also the FDA's warning-letter actions, GLP-1 Solution, 09/09/2025). An adverse reaction to a mislabeled or contaminated product is not a "retatrutide side effect" — it is a product-quality event.
• There is no dose control. The trial side-effect profile depends on a careful starting dose and titration. The dose-dependent GI and heart-rate findings above are the trial's own evidence that getting the dose wrong makes the harms worse.
• There is no monitoring. The trial caught the heart-rate rise, the ALT bump, and the lipase changes because clinicians were measuring them. Unsupervised use has none of that safety net.

This is the core of Peptevity's position: we will report what the trials documented precisely, and we will not launder anecdote into evidence. The gap between "side effects observed in a monitored Phase 3 trial" and "what happens with an unverified vial and no oversight" is the whole point of this page. For the broader framing, see our note on what "research use only" means and the signature explainer on animal versus human peptide evidence.

Honest bottom line

Retatrutide's documented side-effect profile, through Phase 2 and the first Phase 3 readouts, is coherent and class-typical: predominantly gastrointestinal (nausea, diarrhea, vomiting, constipation), clearly dose-dependent, worst during dose escalation, mostly mild-to-moderate, with a small minority discontinuing for that reason. The trials also recorded a modest, dose-dependent heart-rate increase that peaked at week 24 and declined, alongside low-frequency liver-enzyme, pancreatic-enzyme, and skin-sensitivity findings worth naming but not catastrophizing. That is a Grade B human-trial picture — genuine, but still accumulating, because the drug is mid-Phase 3 and long-term outcome data are not in. And it was drawn entirely from supervised use of a controlled product. Retatrutide is not FDA-approved as of June 2026 and is legally available only inside Lilly's trials; side effects reported from gray-market vials are anecdote layered on top of product-quality unknowns. For mechanism, efficacy, and dosing-by-trial design, read the complete retatrutide monograph; for the dated legal picture, see the 2026 regulatory tracker.

Frequently asked questions

What are the most common side effects of retatrutide? In Eli Lilly's trials, the most common side effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation. They were dose-dependent (more frequent at higher doses), clustered during the dose-escalation period, and were predominantly mild-to-moderate (NEJM Phase 2, 2023). In the Phase 3 TRIUMPH-1 trial, nausea reached 42.4% at the 12-mg dose versus 14.8% on placebo, with diarrhea, constipation, and vomiting also elevated and dose-related (Lilly TRIUMPH-1, 2026).

Does retatrutide raise heart rate? The Phase 2 trial documented a dose-dependent increase in heart rate that peaked at 24 weeks and then declined; the authors described the increases as similar to those reported for GLP-1 receptor agonists and consistent with glucagon/GLP-1 effects on the heart (NEJM Phase 2, 2023). Secondary summaries of the data place the average peak rise in the range of roughly 5–7 bpm at higher doses. Reported arrhythmias were mostly mild-to-moderate, with one severe prolonged-QT event in a participant also taking the anti-nausea drug ondansetron (NEJM Phase 2, 2023).

Are retatrutide's side effects dangerous? In the trials, serious adverse events occurred at similar rates with retatrutide and placebo (about 4% in both groups in Phase 2), most side effects were mild-to-moderate and transient, and roughly 6–16% of participants discontinued because of side effects versus 0% on placebo (NEJM Phase 2, 2023). That describes monitored use of a controlled product. Side effects from gray-market material — where identity, purity, dose, and monitoring are all unverified — are a different and largely uncharacterized risk that the trials cannot speak to.

Does retatrutide affect the liver or pancreas? In the Phase 2 obesity trial, transient ALT elevations above three times the upper limit of normal occurred in about 1% of participants, and mean liver enzymes were unchanged or lower by week 48; the dedicated fatty-liver (MASLD) Phase 2a study reported no hepatotoxicity signals through 48 weeks (NEJM Phase 2, 2023; Nature Medicine MASLD Phase 2a, 2024 — PMC11271400). Amylase and lipase increases were mostly asymptomatic, but one serious case of acute pancreatitis was reported (NEJM Phase 2, 2023).

Is retatrutide FDA-approved, and can I take it? No. As of June 2026, retatrutide is an investigational drug that is not FDA-approved and is legally available only to participants in Lilly's clinical trials; Lilly states "no one should take anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial" (Lilly). The FDA has issued warning letters to sellers marketing retatrutide as an unapproved drug, including products falsely labeled "for research purposes" or "not for human consumption" (FDA — GLP-1 Solution warning letter, 09/09/2025). Peptevity publishes no dosing or self-administration guidance for any compound.

How we graded this page

Every claim above is tied to its strongest primary source and labeled by evidence type — trial-documented human data versus anecdotal report — per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement.

Primary sources

• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526 (NCT04881760). NEJM
• Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMC11271400
• Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. PR Newswire / Lilly
• Eli Lilly and Company. What to know about retatrutide. Lilly.com
• U.S. Food and Drug Administration. Warning Letter — GLP-1 Solution (715883), September 9, 2025. FDA
• Cleveland Clinic. Pancreatitis. Cleveland Clinic

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Related on Peptevity

• The complete retatrutide monograph — mechanism, efficacy, and dosing-by-trial design.
• Animal versus human peptide evidence — why supervised-trial data does not transfer to unsupervised use.
• What "research use only" means — the RUO label, explained.
• How Peptevity grades evidence — the evidence scale used on this page.
• The 2026 regulatory tracker — dated FDA / investigational status.
• Our medical disclaimer and RUO statement — what this page is and is not.